News & Updates

Show Multimedia Only

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Treatment with semaglutide appears to improve glycaemic control and weight outcomes in patients with schizophrenia receiving second-generation antipsychotics, as shown in a study.

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

a day ago

Rifaximin does not improve survival in severe cirrhosis

a day ago

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

Rifaximin does not improve survival in severe cirrhosis

a day ago

HCPs, patients willing to trade off OCS benefits to avoid side effects

a day ago by

Both patients and healthcare professionals prefer treatment for asthma attacks that avoids the side effects of oral corticosteroids (OCS), and both are willing to trade off benefits, according to a study.

HCPs, patients willing to trade off OCS benefits to avoid side effects

a day ago

Doxycycline shows potential schizophrenia-lowering benefit

a day ago

Psychiatric patients exposed to doxycycline appear to have a reduced risk of schizophrenia, according to a study.

Doxycycline shows potential schizophrenia-lowering benefit

a day ago

Advancing prevention and outpatient care for respiratory infections in primary care

a day ago

As Singapore continues to face a substantial burden of viral and bacterial respiratory infections, timely focus on prevention and optimized outpatient management remains critical for primary care. Organized by the O2 Healthcare Group and sponsored by Pfizer, a recent GP symposium convened healthcare professionals for an evidence-based update on emerging strategies to reduce respiratory morbidity in the community.

Advancing prevention and outpatient care for respiratory infections in primary care

a day ago

Continuous use of TNFi on the rise in pregnant women

11 Dec 2025

A trend toward increased continuous use of tumour necrosis factor inhibitors has been observed throughout gestation, which suggests growing confidence in the safety and effectiveness of this medication during pregnancy, reveals a study.

Continuous use of TNFi on the rise in pregnant women

11 Dec 2025

ICONIC-LEAD affirms oral icotrokinra benefits in plaque psoriasis

11 Dec 2025 by

In the phase III ICONIC-LEAD trial, selective blockade of the interleukin(IL)-23 receptor with the targeted oral peptide icotrokinra is associated with higher rates of skin clearance and symptom relief in adults and adolescents with moderate-to-severe plaque psoriasis.

ICONIC-LEAD affirms oral icotrokinra benefits in plaque psoriasis

11 Dec 2025

Antimicrobial use rises following TNFi initiation in PsA patients

10 Dec 2025

A recent study has noted a temporary increase in antimicrobial use following initiation of tumour necrosis factor inhibitor (TNFi) treatment, with no significant risk in serious infections, among patients with psoriatic arthritis (PsA).

Antimicrobial use rises following TNFi initiation in PsA patients

10 Dec 2025

Nirsevimab cuts RSV burden in newborns

10 Dec 2025 by

A retrospective study from Italy shows an association between nirsevimab prophylaxis and a lower risk of respiratory syncytial virus (RSV) hospitalizations and a milder disease course.

Nirsevimab cuts RSV burden in newborns

10 Dec 2025

Engasertib shows promise in hereditary haemorrhagic telangiectasia

10 Dec 2025

In the treatment of patients with hereditary haemorrhagic telangiectasia (HHT), use of the novel allosteric, selective AKT inhibitor engasertib appears to be safe and reduce the frequency and duration of epistaxis, according to a proof-of-concept study.

Engasertib shows promise in hereditary haemorrhagic telangiectasia

10 Dec 2025

News & Updates

Filter by Specialty:

Specialty:

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Rifaximin does not improve survival in severe cirrhosis

Rifaximin does not improve survival in severe cirrhosis

HCPs, patients willing to trade off OCS benefits to avoid side effects

HCPs, patients willing to trade off OCS benefits to avoid side effects

Doxycycline shows potential schizophrenia-lowering benefit

Doxycycline shows potential schizophrenia-lowering benefit

Advancing prevention and outpatient care for respiratory infections in primary care

Advancing prevention and outpatient care for respiratory infections in primary care

Continuous use of TNFi on the rise in pregnant women

Continuous use of TNFi on the rise in pregnant women

ICONIC-LEAD affirms oral icotrokinra benefits in plaque psoriasis

ICONIC-LEAD affirms oral icotrokinra benefits in plaque psoriasis

Antimicrobial use rises following TNFi initiation in PsA patients

Antimicrobial use rises following TNFi initiation in PsA patients

Nirsevimab cuts RSV burden in newborns

Nirsevimab cuts RSV burden in newborns

Engasertib shows promise in hereditary haemorrhagic telangiectasia

Engasertib shows promise in hereditary haemorrhagic telangiectasia